The Guinea Pig as a Model for Sporadic Alzheimer's Disease (AD): The Impact of Cholesterol Intake on Expression of AD-Related Genes

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Sharman, Mathew J ^a,b   Moussavi Nik, Seyyed H ^c   Chen, Mengqi M ^a   Ong, Daniel ^a   Wijaya, Linda ^a   Laws, Simon M ^a   Taddei, Kevin ^a,d,e   Newman, Morgan ^c   Lardelli, Michael ^c   Martins, Ralph N ^a,d,e   Verdile, Giuseppe ^a,d,e  

^a EDITH COWAN UNIVERSITY   (Australia)

^b UNIVERSITY OF TASMANIA   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d HOLLYWOOD PRIVATE HOSPITAL   (Australia)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM10 ENDOPEPTIDASE; AMYLOID BETA PROTEIN; BETA SECRETASE 1; CHOLESTEROL; GAMMA SECRETASE; TAU PROTEIN; AMYLOID PRECURSOR PROTEIN; PRESENILIN 1; PRESENILIN 2; SECRETASE;

ADAM10 GENE; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACE1 GENE; BINDING SITE; BRAIN REGION; CHOLESTEROL INTAKE; CONTROLLED STUDY; DISEASE MODEL; DOWN REGULATION; GENE; GENE EXPRESSION; GUINEA PIG; HUMAN; MALE; MAPT GENE; MICROTUBULE; MOUSE; NONHUMAN; PROTEIN DOMAIN; PROTEIN SYNTHESIS; PS2V GENE; PSEN2 GENE; RAT; RISK FACTOR; SEQUENCE HOMOLOGY; SPECIES DIFFERENCE; TRANSCRIPTION REGULATION; UPREGULATION; AMINO ACID SEQUENCE; ANIMAL; BLOOD; BRAIN; CHEMISTRY; DIET; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NUTRITION; PATHOPHYSIOLOGY; PHYSIOLOGY; SEQUENCE ALIGNMENT;

CAVIA; CAVIA PORCELLUS; MUS; RATTUS; RODENTIA;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; BRAIN; CHOLESTEROL; DIET; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; GUINEA PIGS; HUMANS; MICE; NUTRITIONAL PHYSIOLOGICAL PHENOMENA; PRESENILIN-1; PRESENILIN-2; RATS; SEQUENCE ALIGNMENT;

EID: 84879256439     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066235     Document Type: Article

References (70)

1. Elder GA, Gama Sosa MA, De Gasperi R, (2010) Transgenic mouse models of Alzheimer's disease. Mt Sinai J Med 77: 69-81.
2. Epis R, Gardoni F, Marcello E, Genazzani A, Canonico PL, et al. (2010) Searching for new animal models of Alzheimer's disease. Eur J Pharmacol 626: 57-63.
3. Lehman EJ, Kulnane LS, Gao Y, Petriello MC, Pimpis KM, et al. (2003) Genetic background regulates beta-amyloid precursor protein processing and beta-amyloid deposition in the mouse. Hum Mol Genet 12: 2949-2956.
4. Howlett DR, Richardson JC, (2009) The pathology of APP transgenic mice: a model of Alzheimer's disease or simply overexpression of APP? Histol Histopathol 24: 83-100.
5. Ardiles AO, Tapia-Rojas CC, Mandal M, Alexandre F, Kirkwood A, et al. (2012) Postsynaptic dysfunction is associated with spatial and object recognition memory loss in a natural model of Alzheimer's disease. Proc Natl Acad Sci U S A 109: 13835-13840.
6. Beck M, Bigl V, Rossner S, (2003) Guinea pigs as a nontransgenic model for APP processing in vitro and in vivo. Neurochem Res 28: 637-644.
7. Beck M, Muller D, Bigl V, (1997) Amyloid precursor protein in guinea pigs-complete cDNA sequence and alternative splicing. Biochim Biophys Acta 1351: 17-21.
8. Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, et al. (2001) Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci U S A 98: 5856-5861.
9. Mitterreiter S, Page RM, Kamp F, Hopson J, Winkler E, et al. (2010) Bepridil and amiodarone simultaneously target the Alzheimer's disease beta- and gamma-secretase via distinct mechanisms. J Neurosci 30: 8974-8983.
10. Netzer WJ, Dou F, Cai D, Veach D, Jean S, et al. (2003) Gleevec inhibits beta-amyloid production but not Notch cleavage. Proc Natl Acad Sci U S A 100: 12444-12449.
11. Lanz TA, Fici GJ, Merchant KM, (2005) Lack of specific amyloid-beta(1-42) suppression by nonsteroidal anti-inflammatory drugs in young, plaque-free Tg2576 mice and in guinea pig neuronal cultures. J Pharmacol Exp Ther 312: 399-406.
12. Petanceska SS, Nagy V, Frail D, Gandy S, (2000) Ovariectomy and 17beta-estradiol modulate the levels of Alzheimer's amyloid beta peptides in brain. Exp Gerontol 35: 1317-1325.
13. Wahjoepramono EJ, Wijaya LK, Taddei K, Martins G, Howard M, et al. (2008) Distinct effects of testosterone on plasma and cerebrospinal fluid amyloid-beta levels. J Alzheimers Dis 15: 129-137.
14. Wahjoepramono EJ, Wijaya LK, Taddei K, Bates KA, Howard M, et al. (2011) Direct Exposure of Guinea Pig CNS to Human Luteinizing Hormone Increases Cerebrospinal Fluid and Cerebral Beta Amyloid Levels. Neuroendocrinology.
15. Fernandez ML, (2001) Guinea pigs as models for cholesterol and lipoprotein metabolism. J Nutr 131: 10-20.
16. Zern TL, West KL, Fernandez ML, (2003) Grape polyphenols decrease plasma triglycerides and cholesterol accumulation in the aorta of ovariectomized guinea pigs. J Nutr 133: 2268-2272.
17. Sharman MJ, Fernandez ML, Zern TL, Torres-Gonzalez M, Kraemer WJ, et al. (2008) Replacing dietary carbohydrate with protein and fat decreases the concentrations of small LDL and the inflammatory response induced by atherogenic diets in the guinea pig. J Nutr Biochem 19: 732-738.
18. Lin EC, Fernandez ML, McNamara DJ, (1992) Dietary fat type and cholesterol quantity interact to affect cholesterol metabolism in guinea pigs. J Nutr 122: 2019-2029.
19. Cos E, Ramjiganesh T, Roy S, Yoganathan S, Nicolosi RJ, et al. (2001) Soluble fiber and soybean protein reduce atherosclerotic lesions in guinea pigs. Sex and hormonal status determine lesion extension. Lipids 36: 1209-1216.
20. Verdile G, Gnjec A, Miklossy J, Fonte J, Veurink G, et al. (2004) Protein markers for Alzheimer disease in the frontal cortex and cerebellum. Neurology 63: 1385-1392.
21. Schmidt SD, Nixon RA, Mathews PM, (2005) ELISA method for measurement of amyloid-beta levels. Methods Mol Biol 299: 279-297.
22. Mehta PD, Pirttila T, Mehta SP, Sersen EA, Aisen PS, et al. (2000) Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol 57: 100-105.
23. Ringman JM, Gylys KH, Medina LD, Fox M, Kepe V, et al. (2011) Biochemical, neuropathological, and neuroimaging characteristics of early-onset Alzheimer's disease due to a novel PSEN1 mutation. Neurosci Lett 487: 287-292.
24. Rogaev EI, Sherrington R, Wu C, Levesque G, Liang Y, et al. (1997) Analysis of the 5' sequence, genomic structure, and alternative splicing of the presenilin-1 gene (PSEN1) associated with early onset Alzheimer disease. Genomics 40: 415-424.
25. Scheper W, Zwart R, Baas F, (2004) Alternative splicing in the N-terminus of Alzheimer's presenilin 1. Neurogenetics 5: 223-227.
26. Sato N, Hori O, Yamaguchi A, Lambert JC, Chartier-Harlin MC, et al. (1999) A novel presenilin-2 splice variant in human Alzheimer's disease brain tissue. J Neurochem 72: 2498-2505.
27. Sato N, Imaizumi K, Manabe T, Taniguchi M, Hitomi J, et al. (2001) Increased production of beta-amyloid and vulnerability to endoplasmic reticulum stress by an aberrant spliced form of presenilin 2. J Biol Chem 276: 2108-2114.
28. Smith MJ, Sharples RA, Evin G, McLean CA, Dean B, et al. (2004) Expression of truncated presenilin 2 splice variant in Alzheimer's disease, bipolar disorder, and schizophrenia brain cortex. Brain Res Mol Brain Res 127: 128-135.
29. Manabe T, Katayama T, Sato N, Gomi F, Hitomi J, et al. (2003) Induced HMGA1a expression causes aberrant splicing of Presenilin-2 pre-mRNA in sporadic Alzheimer's disease. Cell Death Differ 10: 698-708.
30. Matsuzaki S, Manabe T, Katayama T, Nishikawa A, Yanagita T, et al. (2004) Metals accelerate production of the aberrant splicing isoform of the presenilin-2. J Neurochem 88: 1345-1351.
31. Crestini A, Napolitano M, Piscopo P, Confaloni A, Bravo E, (2006) Changes in cholesterol metabolism are associated with PS1 and PS2 gene regulation in SK-N-BE. J Mol Neurosci 30: 311-322.
32. Sparks DL, Scheff SW, Hunsaker JC 3rd, Liu H, Landers T, et al (1994) Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol 126: 88-94.
33. Sparks DL, Kuo YM, Roher A, Martin T, Lukas RJ, (2000) Alterations of Alzheimer's disease in the cholesterol-fed rabbit, including vascular inflammation. Preliminary observations. Ann N Y Acad Sci 903: 335-344.
34. Refolo LM, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, et al. (2000) Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis 7: 321-331.
35. Refolo LM, Pappolla MA, LaFrancois J, Malester B, Schmidt SD, et al. (2001) A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis 8: 890-899.
36. Jaya Prasanthi RP, Schommer E, Thomasson S, Thompson A, Feist G, et al. (2008) Regulation of beta-amyloid levels in the brain of cholesterol-fed rabbit, a model system for sporadic Alzheimer's disease. Mech Ageing Dev 129: 649-655.
37. Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, et al. (2010) Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 142: 387-397.
38. Haass C, Mandelkow E, (2010) Fyn-tau-amyloid: a toxic triad. Cell 142: 356-358.
39. Lee G, Cowan N, Kirschner M, (1988) The primary structure and heterogeneity of tau protein from mouse brain. Science 239: 285-288.
40. Miller JA, Horvath S, Geschwind DH, (2010) Divergence of human and mouse brain transcriptome highlights Alzheimer disease pathways. Proc Natl Acad Sci U S A 107: 12698-12703.
41. Sato C, Takagi S, Tomita T, Iwatsubo T, (2008) The C-terminal PAL motif and transmembrane domain 9 of presenilin 1 are involved in the formation of the catalytic pore of the gamma-secretase. J Neurosci 28: 6264-6271.
42. Tolia A, Chavez-Gutierrez L, De Strooper B, (2006) Contribution of presenilin transmembrane domains 6 and 7 to a water-containing cavity in the gamma-secretase complex. J Biol Chem 281: 27633-27642.
43. Tolia A, Horre K, De Strooper B, (2008) Transmembrane domain 9 of presenilin determines the dynamic conformation of the catalytic site of gamma-secretase. J Biol Chem 283: 19793-19803.
44. Gong P, Vetrivel KS, Nguyen PD, Meckler X, Cheng H, et al. (2010) Mutation analysis of the presenilin 1 N-terminal domain reveals a broad spectrum of gamma-secretase activity toward amyloid precursor protein and other substrates. J Biol Chem 285: 38042-38052.
45. Takagi S, Tominaga A, Sato C, Tomita T, Iwatsubo T, (2010) Participation of transmembrane domain 1 of presenilin 1 in the catalytic pore structure of the gamma-secretase. J Neurosci 30: 15943-15950.
46. Wanngren J, Franberg J, Svensson AI, Laudon H, Olsson F, et al. (2010) The large hydrophilic loop of presenilin 1 is important for regulating gamma-secretase complex assembly and dictating the amyloid beta peptide (Abeta) Profile without affecting Notch processing. J Biol Chem 285: 8527-8536.
47. Dumanchin C, Czech C, Campion D, Cuif MH, Poyot T, et al. (1999) Presenilins interact with Rab11, a small GTPase involved in the regulation of vesicular transport. Human molecular genetics 8: 1263-1269.
48. Tanahashi H, Tabira T, (1999) Isolation of human delta-catenin and its binding specificity with presenilin 1. Neuroreport 10: 563-568.
49. Zhang W, Han SW, McKeel DW, Goate A, Wu JY, (1998) Interaction of presenilins with the filamin family of actin-binding proteins. J Neurosci 18: 914-922.
50. Smith SK, Anderson HA, Yu G, Robertson AG, Allen SJ, et al. (2000) Identification of syntaxin 1A as a novel binding protein for presenilin-1. Brain Res Mol Brain Res 78: 100-107.
51. George AJ, Holsinger RM, McLean CA, Laughton KM, Beyreuther K, et al. (2004) APP intracellular domain is increased and soluble Abeta is reduced with diet-induced hypercholesterolemia in a transgenic mouse model of Alzheimer disease. Neurobiol Dis 16: 124-132.
52. Kojro E, Gimpl G, Lammich S, Marz W, Fahrenholz F, (2001) Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha-secretase ADAM 10. Proc Natl Acad Sci U S A 98: 5815-5820.
53. Murphy MP, Morales J, Beckett TL, Astarita G, Piomelli D, et al. (2010) Changes in cognition and amyloid-beta processing with long term cholesterol reduction using atorvastatin in aged dogs. J Alzheimers Dis 22: 135-150.
54. Wu CW, Liao PC, Lin C, Kuo CJ, Chen ST, et al. (2003) Brain region-dependent increases in beta-amyloid and apolipoprotein E levels in hypercholesterolemic rabbits. J Neural Transm 110: 641-649.
55. Irizarry MC, Locascio JJ, Hyman BT, (2001) beta-site APP cleaving enzyme mRNA expression in APP transgenic mice: anatomical overlap with transgene expression and static levels with aging. Am J Pathol 158: 173-177.
56. Yasojima K, McGeer EG, McGeer PL, (2001) Relationship between beta amyloid peptide generating molecules and neprilysin in Alzheimer disease and normal brain. Brain Res 919: 115-121.
57. Bigl M, Apelt J, Luschekina EA, Lange-Dohna C, Rossner S, et al. (2000) Expression of beta-secretase mRNA in transgenic Tg2576 mouse brain with Alzheimer plaque pathology. Neurosci Lett 292: 107-110.
58. Rossner S, Apelt J, Schliebs R, Perez-Polo JR, Bigl V, (2001) Neuronal and glial beta-secretase (BACE) protein expression in transgenic Tg2576 mice with amyloid plaque pathology. J Neurosci Res 64: 437-446.
59. Higashide S, Morikawa K, Okumura M, Kondo S, Ogata M, et al. (2004) Identification of regulatory cis-acting elements for alternative splicing of presenilin 2 exon 5 under hypoxic stress conditions. J Neurochem 91: 1191-1198.
60. Skoog I, Gustafson D, (2006) Update on hypertension and Alzheimer's disease. Neurological research 28: 605-611.
61. Liu H, Xing A, Wang X, Liu G, Li L, (2012) Regulation of beta amyloid level in the brain of rats with cerebrovascular hypoperfusion. Neurobiology of Aging 33: 826.e831-826.e842.
62. Zetterberg H, Mortberg E, Song L, Chang L, Provuncher GK, et al. (2011) Hypoxia due to cardiac arrest induces a time-dependent increase in serum amyloid beta levels in humans. PloS one 6: e28263.
63. Tamagno E, Guglielmotto M, Aragno M, Borghi R, Autelli R, et al. (2008) Oxidative stress activates a positive feedback between the gamma- and beta-secretase cleavages of the beta-amyloid precursor protein. J Neurochem 104: 683-695.
64. Moussavi Nik SH, Newman M, Lardelli M, (2011) The response of HMGA1 to changes in oxygen availability is evolutionarily conserved. Exp Cell Res 317: 1503-1512.
65. Takuma H, Arawaka S, Mori H, (2003) Isoforms changes of tau protein during development in various species. Brain Res Dev Brain Res 142: 121-127.
66. Ginsberg SD, Che S, Counts SE, Mufson EJ, (2006) Shift in the ratio of three-repeat tau and four-repeat tau mRNAs in individual cholinergic basal forebrain neurons in mild cognitive impairment and Alzheimer's disease. J Neurochem 96: 1401-1408.
67. Conrad C, Zhu J, Conrad C, Schoenfeld D, Fang Z, et al. (2007) Single molecule profiling of tau gene expression in Alzheimer's disease. J Neurochem 103: 1228-1236.
68. Connell JW, Rodriguez-Martin T, Gibb GM, Kahn NM, Grierson AJ, et al. (2005) Quantitative analysis of tau isoform transcripts in sporadic tauopathies. Brain Res Mol Brain Res 137: 104-109.
69. Espinoza M, de Silva R, Dickson DW, Davies P, (2008) Differential incorporation of tau isoforms in Alzheimer's disease. J Alzheimers Dis 14: 1-16.
70. Jung HJ, Park SS, Mok JO, Lee TK, Park CS, et al. (2011) Increased expression of three-repeat isoforms of tau contributes to tau pathology in a rat model of chronic type 2 diabetes. Exp Neurol 228: 232-241.